Salarius Pharmaceuticals released FY2024 Semi-Annual earnings on August 9 (EST) with actual revenue of USD 0 and EPS of USD 0

Brief Summary

Salarius Pharmaceuticals reported its 2024 fiscal half-year results with zero revenue and zero earnings per share, indicating poor financial performance compared to peers like AMD and Apple who reported substantial revenue growth in their recent financial reports.

Impact of The News

Salarius Pharmaceuticals’ financial results for the first half of 2024 show zero revenue and zero earnings per share, suggesting significant challenges in its business operations. This is in stark contrast to companies like AMD, which reported a 31.7% year-over-year growth in revenue for the second quarter of 2025, and Apple, which saw a 9.6% increase in revenue for the third quarter of 2025. The lack of revenue and profit generation for Salarius Pharmaceuticals is likely to lead to investor concerns and could impact its stock price negatively. The company’s financial status indicates potential difficulties in product development, commercialization, or market demand, which might necessitate strategic changes or restructuring to improve financial health. Compared to its peers, Salarius needs to address its operational inefficiencies to avoid further deterioration in its business prospects.